Regorafenib Combined with BRAF/MEK Inhibitors for the Treatment of Refractory Melanoma Brain Metastases.

ABSTRACT:

Background

There are no active treatment options for patients with progressive melanoma brain metastases (MBM) failing immune checkpoint blockade (ICB) and BRAF/MEK inhibitors (BRAF/MEKi). Regorafenib (REGO), an oral multi-kinase inhibitor (incl. RAF-dimer inhibition), can overcome adaptive resistance to BRAF/MEKi in preclinical models.

Methods

This is a single-center retrospective case series of patients with refractory MBM treated with REGO plus BRAF/MEKi (compassionate use).

Results

A total of 22 patients were identified (18 BRAF-mutant, 4 NRAS^Q61-mutant; 19 with progressive MBM; 11 on corticosteroids). Thirteen BRAF^V600-mutant patients were progressing on BRAF/MEKi at the time of REGO association. BRAF-mutant patie

SUBMITTER: Dirven I 

PROVIDER: S-EPMC11640054 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature